The combination of strong top-line growth, expanding profitability, rising backlog, and new FDA clearances suggests accelerating commercial momentum. Traders should monitor execution against the aggressive 2026 EBITDA guidance and adoption of the new adolescent and SWIFT protocols as key catalysts.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 11 $13.77entry
- T+1 · 8mo ago −0.22%α +1.27% · $13.74
- T+5 · 8mo ago −2.40%α −0.21% · $13.44
- T+20 · 7mo ago +3.85%α +3.33% · $14.30
- T+60 · 5mo ago +1.96%α −9.56% · $14.04
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BrainsWay reported strong Q4 and full-year 2025 results with 27% YoY revenue growth to $52.2 million, net income up 161% to $7.6 million, and raised 2026 guidance projecting $66–68 million in revenue (27–30% growth) and Adjusted EBITDA of $12–14 million (86–100% growth). The company also secured FDA clearances for adolescent depression and an accelerated treatment protocol, expanding its market potential.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $14.5M (+27% YoY)
- Full-year 2025 revenue: $52.2M (+27% YoY)
- Full-year 2025 net income: $7.6M (+161% YoY)
- Adjusted EBITDA for 2025: $7.0M (+55% YoY)
- Remaining performance obligations up 43% to $70M
- 2026 revenue guidance: $66M–$68M (27–30% growth)
- 2026 Adjusted EBITDA guidance: $12M–$14M (86–100% growth)
- FDA cleared Deep TMS for adolescents (15–21) with MDD and approved accelerated SWIFT™ protocol
Financial Impact
Revenue growth accelerating at scale with expanding margins; $18M midpoint increase in Adjusted EBITDA expected in 2026
Risk Factors
- Forward-looking guidance may not be achieved
- High growth expectations already priced into stock (OTC market, $961M market cap)
- Cash balance declined slightly despite strong net income due to working capital outflows
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253665 |
Track record
24 reports on BWAY
5 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +27.55% at T+60 after the Mar 4, 2026 report. 7 of 10 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Bullish 6/10 No price data
- Nov 10, 20266d ago 6-K Neutral 5/10 Entry $10.67 Now $9.39 −12.00% settles Dec 9
- Nov 2, 202614d ago 6-K Neutral 3/10 Entry $11.09 Now $9.39 −15.33% settles Dec 1
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $11.09 Now $9.39 −15.33% settles Dec 1
- Oct 26, 202621d ago 6-K Neutral 3/10 Entry $11.21 Now $9.39 −16.24% settles Nov 23
- Oct 21, 202626d ago 6-K Neutral 3/10 Entry $11.44 Now $9.39 −17.92% settles Nov 19
- Oct 19, 202628d ago 6-K Neutral 3/10 Entry $11.99 Now $9.39 −21.68% due Nov 16
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $11.99 Now $9.39 −21.68% due Nov 16
- Oct 13, 20264w ago 6-K Neutral 4/10 Entry $11.92 to $10.67 Now $9.39 −21.22% ▼ −10.49% −6.88% vs SPY
- Sep 8, 20269w ago 6-K Neutral 4/10 Entry $14.16 to $11.89 Now $9.39 −33.69% ▼ −16.03% −18.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers